Archives
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
Phalloidin B7678: F-Actin Workflow Guide
2026-09-03
Phalloidin B7678 is a high-affinity F-actin probe for preserving and visualizing filament organization in fixed or permeabilized samples. It supports static cytoskeleton visualization but should not be used for live-cell imaging, reversible actin studies, or direct measurement of monomeric G-actin.
-
Imidazoline Antagonists and β-Cell K+ Channels
2026-09-02
Jonas, Plant, and Henquin showed that several imidazoline α2-adrenoceptor antagonists stimulate insulin release primarily by inhibiting ATP-sensitive K+ channels in pancreatic β-cells, rather than simply by blocking adrenergic receptors. Their combination of insulin secretion assays, 86Rb efflux measurements, and patch-clamp recordings provides a useful framework for separating receptor-mediated effects from direct ion-channel actions.
-
LY2603618: Selective Chk1 Inhibitor Guide
2026-09-02
LY2603618 is an ATP-competitive Chk1 inhibitor for laboratory studies of DNA damage response, checkpoint control, and cancer chemotherapy sensitization. Product-reported activity includes G2/M disruption, increased H2AX phosphorylation, and enhanced gemcitabine-associated DNA damage in a Calu-6 xenograft model.
-
Adamtsl3, MMP9, and Cortical Plasticity
2026-09-01
The reference study identifies Adamtsl3 as a cell-autonomous regulator of perineuronal-net integrity in parvalbumin-positive interneurons and connects its loss to elevated MMP9 activity, oxidative stress, and renewed adult cortical plasticity. Its combination of mouse genetics, extracellular-matrix imaging, biochemical analysis, and pharmacological rescue provides a framework for testing how schizophrenia-associated genes influence circuit stability.
-
Risedronate Sodium: FPPS Mechanism & Research Use
2026-09-01
Risedronate Sodium is a nitrogen-containing bisphosphonate and FPP synthase inhibitor that suppresses osteoclast-mediated bone resorption. Formulation research, including nanotransfersomes and dissolving microneedles, addresses its low oral bioavailability while providing measurable ex vivo delivery benchmarks.
-
Machine Learning for Senolytic Discovery
2026-08-31
The reference study shows that machine learning trained on small, heterogeneous published datasets can identify senolytic candidates without requiring a fully defined molecular target. Its validation of ginkgetin, periplocin, and oleandrin provides a practical framework for prioritizing compounds while emphasizing the need for cell-selectivity and orthogonal experimental testing.
-
CBD, Orofacial Pain, and Affective Deficits
2026-08-31
A 2026 Brain Research Bulletin study shows that cannabidiol (CBD) can reduce inflammatory nociception while also improving anxiety-like, depression-like, and cognitive abnormalities in mouse pain models. Its main contribution is a mechanistic framework linking peripheral endocannabinoid signaling, trigeminal and cortical activity, and serotonin dynamics in the central amygdala.
-
Triamcinolone B1859: Practical Lab Guide
2026-08-30
This guide explains how to prepare, control, and evaluate Triamcinolone B1859 in research workflows involving glucocorticoid signaling, inflammation, and immunosuppression. It is intended for controlled scientific use only and should not be used for diagnostic, clinical, or therapeutic applications.
-
Quinolone–Coumarin Hybrids Against Toxoplasma gondii
2026-08-29
A 2024 Acta Parasitologica study evaluated twelve quinolone–coumarin hybrids derived from fluoroquinolones and novobiocin against Toxoplasma gondii in vitro. QC1, QC3, QC6, and novobiocin combined reduced apparent parasite infection and proliferation with comparatively limited host-cell toxicity, identifying a focused set of leads for further anti-Toxoplasma research.
-
DNA Frameworks Improve Enzymatic Oligonucleotide Synthesis
2026-08-28
The reference study introduces tetrahedral DNA nanostructures as an ordered interface for improving enzymatic oligonucleotide synthesis. By controlling primer orientation and spacing, the framework increases enzyme accessibility, reduces deletion errors, and supports accurate synthesis of a 60-nucleotide DNA information-storage sequence.
-
Sulfisomidine Workflows for hPON1 and Microbes
2026-08-28
Sulfisomidine, also known as sulfamethin, supports two complementary research workflows: mechanistic hPON1 inhibition assays and bacterial folate-pathway experiments. This guide translates its mixed-type inhibition profile, formulation constraints, and assay behavior into practical protocols, controls, and troubleshooting decisions.
-
Tacrolimus (FK506) at the Metabolic-Immune Interface
2026-08-27
Tacrolimus (FK506) is best known as a potent FKBP12–calcineurin inhibitor for T-cell and cytokine studies. New findings on the AMPK–SQSTM1/p62 antioxidant feedback loop create a useful translational question: how can a defined immune perturbation help researchers distinguish cytokine-driven effects from metabolic-stress adaptation?
-
ARCA and the Next Wave of Translational mRNA
2026-08-27
How orientation-specific mRNA capping connects molecular design with delivery, translation, and translational decision-making in advanced research programs.
-
WAY-100635: A Causal Probe for Pain Circuits
2026-08-26
WAY-100635 enables rigorous serotonin receptor antagonist research by testing whether 5-HT1A signaling contributes to sensory, affective, and cognitive pain phenotypes. This article translates recent cannabidiol findings into a practical, receptor-level assay strategy while defining key pharmacological limitations.
-
EcYqfB and the Structural Biology of ac4C Processing
2026-08-26
Meng et al. define how the ASCH-domain enzyme EcYqfB hydrolyzes free N4-acetylcytidine into cytidine while showing that it does not remove ac4C from RNA. Structures of EcYqfB, mouse EOLA1, and the human TRIP4-ASCH domain further distinguish catalytic substrate recognition from broader nucleic-acid binding, providing a useful framework for RNA modification and nucleotide-processing studies.